source
- J&J shares fall 3% as oncology sales miss forecasts, while AstraZeneca invests $600M in lung cancer drugJohnson & Johnson’s stock slipped about 3% on Wednesday even though the company raised its full‑year sales outlook. In its latest quarterly earnings release the firm said revenue in its innovative…
- Biogen’s experimental Alzheimer’s therapy shows comparable slowing of cognitive decline in mid-stage trial, paving way to Phase 3Biogen reported that its experimental Alzheimer’s drug slowed cognitive decline in a mid-stage study. The trial showed patients experienced a rate of decline similar to that seen with currently app…